Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H17N4OS.Cl.ClH |
Molecular Weight | 337.269 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC2=C(N)N=C(C)N=C2
InChI
InChIKey=DPJRMOMPQZCRJU-UHFFFAOYSA-M
InChI=1S/C12H17N4OS.2ClH/c1-8-11(3-4-17)18-7-16(8)6-10-5-14-9(2)15-12(10)13;;/h5,7,17H,3-4,6H2,1-2H3,(H2,13,14,15);2*1H/q+1;;/p-1
Molecular Formula | C12H16N4OS |
Molecular Weight | 264.347 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Thiamine, also known as vitamin B1, plays a key role in the human metabolism. It is present in many dietary sources such as meats, eggs, fish, beans and peas, nuts, and whole grains. Upon administration thiamine is converted by thiamine
pyrophosphokinase-1 (TPK1) to the active form, thiamine pyrophosphate, which serves as a cofactor for enzymes involved in the TCA cycle and the non-oxidative part of the pentose phosphate pathway. The lack of thiamine may cause the thiamine deficiency. The classical syndrome caused primarily by thiamine deficiency in humans is beriberi, however, symptoms of thiamine deficiency also include congestive heart failure, metabolic acidosis, confusion, ataxia and seizures. Thiamine is a component of many vitamin complexes, which are approved for the treatmen and prevention of general vitamin deficiency, including the thiamine deficiency.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7120152
Curator's Comment: The transport of thiamine across the blood brain barrier was shown in rats.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q9H3S4 Gene ID: 27010.0 Gene Symbol: TPK1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/16550223 |
|||
Target ID: GO:0005975 |
|||
Target ID: WP408 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | M.V.I.-12 Approved UseM.V.I.-12 Unit Vial, is indicated for the prevention of vitamin deficiency in adults and children aged 11 years and above who are on warfarin anticoagulant therapy receiving home parenteral nutrition. Launch Date1953 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
40 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
39 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
95 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
113 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
386 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
397 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
214 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
177 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
623 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
612 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2046 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2059 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.92 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
4.78 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2.97 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
Sources: https://go.drugbank.com/drugs/DB00152 |
yes | |||
Sources: https://go.drugbank.com/drugs/DB00152 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://go.drugbank.com/drugs/DB00152 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Cloning of the human thiamine transporter, a member of the folate transporter family. | 1999 Nov 5 |
|
Effect of thiamine hydrochloride on lead induced lipid peroxidation in rat liver and kidney. | 2000 Aug |
|
Mitochondrial myopathy and familial thiamine deficiency. | 2000 Jul |
|
Low plasma thiamine levels in elder patients admitted through the emergency department. | 2000 Oct |
|
[Evaluation of vitamin and immune status of patients with chronic palatal tonsillitis]. | 2001 |
|
Effects of vitamins on hepatic nuclear binding of L-tryptophan. | 2001 |
|
Thiamine-responsive acute neurological disorders in nonalcoholic patients. | 2001 |
|
Nutritional evaluation of ethanol-extracted lentil flours. | 2001 Apr |
|
Analysis of slc19a2, on 1q23.3 encoding a thiamine transporter as a candidate gene for type 2 diabetes mellitus in pima indians. | 2001 Apr |
|
Suppression of the accumulation of triosephosphates and increased formation of methylglyoxal in human red blood cells during hyperglycaemia by thiamine in vitro. | 2001 Apr |
|
The multifaceted and widespread pathology of magnesium deficiency. | 2001 Feb |
|
Aroma extract dilution analysis of a beeflike process flavor from extruded enzyme-hydrolyzed soybean protein. | 2001 Feb |
|
Evidence for non-enzymatic glycosylation in Escherichia coli. | 2001 Feb |
|
In vivo and in vitro proton NMR spectroscopic studies of thiamine-deficient rat brains. | 2001 Feb |
|
Chorea induced by thiamine deficiency in hemodialysis patients. | 2001 Feb |
|
Glucose induced IEG expression in the thiamin-deficient rat brain. | 2001 Feb 16 |
|
Probing the mechanism of inactivation of human pyruvate dehydrogenase by phosphorylation of three sites. | 2001 Feb 23 |
|
Cresol red thallium acetate sucrose inulin (CTSI) agar for the selective recovery of Carnobacterium spp. | 2001 Feb 28 |
|
Nutritional evaluation of some processed catering foods. | 2001 Jan |
|
Thiamin treatment and working memory function of alcohol-dependent people: preliminary findings. | 2001 Jan |
|
Manothermosonication of foods and food-resembling systems: effect on nutrient content and nonenzymatic browning. | 2001 Jan |
|
In vivo microdialysis in an animal model of neurological disease: thiamine deficiency (Wernicke) encephalopathy. | 2001 Jan |
|
Solution structure of ThiS and implications for the evolutionary roots of ubiquitin. | 2001 Jan |
|
Impact of the reduced folate carrier on the accumulation of active thiamin metabolites in murine leukemia cells. | 2001 Jan 12 |
|
Molecular cloning of human thiamin pyrophosphokinase. | 2001 Jan 26 |
|
Isolation and characterization of a human thiamine pyrophosphokinase cDNA. | 2001 Jan 26 |
|
Thiamine-responsive megaloblastic anemia syndrome: a disorder of high-affinity thiamine transport. | 2001 Jan-Feb |
|
Vitamin requirements of the cultured flesh fly cells, Sarcophaga peregrina (Diptera, Sarcophagidae). | 2001 Jan-Feb |
|
Effects of glucose, vitamins, and DO concentrations on pyruvate fermentation using Torulopsis glabrata IFO 0005 with metabolic flux analysis. | 2001 Jan-Feb |
|
Low thiamine intake and risk of cataract. | 2001 Jul |
|
Nerve conduction changes in patients with mitochondrial diseases treated with dichloroacetate. | 2001 Jul |
|
Mechanism of thiamine uptake by human colonocytes: studies with cultured colonic epithelial cell line NCM460. | 2001 Jul |
|
No association between DLST gene and Alzheimer's disease or Wernicke-Korsakoff syndrome. | 2001 Jul-Aug |
|
Vitamin B intake and status in healthy Havanan men, 2 years after the Cuban neuropathy epidemic. | 2001 Jun |
|
Sulfur compounds reduce potato toxins during extrusion cooking. | 2001 Jun |
|
Slc19a2: cloning and characterization of the murine thiamin transporter cDNA and genomic sequence, the orthologue of the human TRMA gene. | 2001 Jun |
|
Simultaneous determination of thiamine and pyridoxine in pharmaceuticals by using a single flow-through biparameter sensor. | 2001 Jun |
|
Comparison of ion-pair and amide-based column reversed-phase liquid chromatography for the separation of thiamine-related compounds. | 2001 Jun 15 |
|
Catalytic acid-base groups in yeast pyruvate decarboxylase. 1. Site-directed mutagenesis and steady-state kinetic studies on the enzyme with the D28A, H114F, H115F, and E477Q substitutions. | 2001 Jun 26 |
|
Crystal structure of thiamin pyrophosphokinase. | 2001 Jun 29 |
|
Relationships between dietary intake and cognitive function level in Korean elderly people. | 2001 Mar |
|
The value of oral thiamine. | 2001 Mar-Apr |
|
[Other drugs administered with TPN solution]. | 2001 May |
|
[Metabolic acidosis induced by TPN]. | 2001 May |
|
Wernicke's encephalopathy in a non-alcoholic man: case report and brief review. | 2001 May |
|
Application of liquid chromatography to the simultaneous determination of acetylsalicylic acid, caffeine, codeine, paracetamol, pyridoxine, and thiamine in pharmaceutical preparations. | 2001 May-Jun |
|
The role of the cysteine residues of ThiI in the generation of 4-thiouridine in tRNA. | 2001 Sep 7 |
Patents
Sample Use Guides
The starting dose (as a component of M.V.I.–12) is one 10 mL daily dose added directly to an intravenous fluid.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10516094
Human Caco-2 cells were incubated (37 Celsius) in Krebs-Ringer buffer (pH 7.4) for different periods of time in the presence of 0.1 uM and 10 uM thiamine. The uptake study demonstrated that thiamine is transported across the cell membrane with Michaelis-Menten constant of 3.18 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:45:54 GMT 2025
by
admin
on
Mon Mar 31 18:45:54 GMT 2025
|
Record UNII |
M572600E5P
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 310.529
Created by
admin on Mon Mar 31 18:45:54 GMT 2025 , Edited by admin on Mon Mar 31 18:45:54 GMT 2025
|
||
|
NCI_THESAURUS |
C26017
Created by
admin on Mon Mar 31 18:45:54 GMT 2025 , Edited by admin on Mon Mar 31 18:45:54 GMT 2025
|
||
|
CFR |
21 CFR 184.1875
Created by
admin on Mon Mar 31 18:45:54 GMT 2025 , Edited by admin on Mon Mar 31 18:45:54 GMT 2025
|
||
|
JECFA EVALUATION |
THIAMINE HYDROCHLORIDE
Created by
admin on Mon Mar 31 18:45:54 GMT 2025 , Edited by admin on Mon Mar 31 18:45:54 GMT 2025
|
||
|
DSLD |
2667 (Number of products:2178)
Created by
admin on Mon Mar 31 18:45:54 GMT 2025 , Edited by admin on Mon Mar 31 18:45:54 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6202
Created by
admin on Mon Mar 31 18:45:54 GMT 2025 , Edited by admin on Mon Mar 31 18:45:54 GMT 2025
|
PRIMARY | |||
|
963
Created by
admin on Mon Mar 31 18:45:54 GMT 2025 , Edited by admin on Mon Mar 31 18:45:54 GMT 2025
|
PRIMARY | |||
|
DTXSID0040622
Created by
admin on Mon Mar 31 18:45:54 GMT 2025 , Edited by admin on Mon Mar 31 18:45:54 GMT 2025
|
PRIMARY | |||
|
M572600E5P
Created by
admin on Mon Mar 31 18:45:54 GMT 2025 , Edited by admin on Mon Mar 31 18:45:54 GMT 2025
|
PRIMARY | |||
|
m10717
Created by
admin on Mon Mar 31 18:45:54 GMT 2025 , Edited by admin on Mon Mar 31 18:45:54 GMT 2025
|
PRIMARY | Merck Index | ||
|
49105
Created by
admin on Mon Mar 31 18:45:54 GMT 2025 , Edited by admin on Mon Mar 31 18:45:54 GMT 2025
|
PRIMARY | |||
|
SUB04798MIG
Created by
admin on Mon Mar 31 18:45:54 GMT 2025 , Edited by admin on Mon Mar 31 18:45:54 GMT 2025
|
PRIMARY | |||
|
200-641-8
Created by
admin on Mon Mar 31 18:45:54 GMT 2025 , Edited by admin on Mon Mar 31 18:45:54 GMT 2025
|
PRIMARY | |||
|
100000091092
Created by
admin on Mon Mar 31 18:45:54 GMT 2025 , Edited by admin on Mon Mar 31 18:45:54 GMT 2025
|
PRIMARY | |||
|
235355
Created by
admin on Mon Mar 31 18:45:54 GMT 2025 , Edited by admin on Mon Mar 31 18:45:54 GMT 2025
|
PRIMARY | RxNorm | ||
|
36226
Created by
admin on Mon Mar 31 18:45:54 GMT 2025 , Edited by admin on Mon Mar 31 18:45:54 GMT 2025
|
PRIMARY | |||
|
1656002
Created by
admin on Mon Mar 31 18:45:54 GMT 2025 , Edited by admin on Mon Mar 31 18:45:54 GMT 2025
|
PRIMARY | |||
|
DBSALT000205
Created by
admin on Mon Mar 31 18:45:54 GMT 2025 , Edited by admin on Mon Mar 31 18:45:54 GMT 2025
|
PRIMARY | |||
|
M572600E5P
Created by
admin on Mon Mar 31 18:45:54 GMT 2025 , Edited by admin on Mon Mar 31 18:45:54 GMT 2025
|
PRIMARY | |||
|
THIAMINE HYDROCHLORIDE
Created by
admin on Mon Mar 31 18:45:54 GMT 2025 , Edited by admin on Mon Mar 31 18:45:54 GMT 2025
|
PRIMARY | Description: Colourless crystals or a white or yellowish white, crystalline powder; odour, slight and characteristic. Solubility: Soluble in 1 part of water and in 100 parts of ethanol (~750 g/l) TS; practically insoluble in acetone R and ether R. Category: Component of vitamin B. Storage: Thiamine hydrochloride should be kept in a tightly closed, non-metallic container, protected from light. Additional information: Even in the absence of light, Thiamine hydrochloride is gradually degraded on exposure to a humidatmosphere, the decomposition being faster at higher temperatures. When exposed to air, the anhydrous product rapidly absorbsabout 4 g of water per 100 g. Melting temperature, about 248 ?C with some decomposition. In solution at pH 4.0 or less, it loses its activity only very slowly. Neutral and alkaline solutions deteriorate rapidly, especially in contact with air. Definition: Thiamine hydrochloride contains not less than 98.0% and not more than 101.0% of C12H17ClN4OS,HCl, calculated with reference to the dried substance. | ||
|
C48025
Created by
admin on Mon Mar 31 18:45:54 GMT 2025 , Edited by admin on Mon Mar 31 18:45:54 GMT 2025
|
PRIMARY | |||
|
67-03-8
Created by
admin on Mon Mar 31 18:45:54 GMT 2025 , Edited by admin on Mon Mar 31 18:45:54 GMT 2025
|
PRIMARY | |||
|
CHEMBL1547
Created by
admin on Mon Mar 31 18:45:54 GMT 2025 , Edited by admin on Mon Mar 31 18:45:54 GMT 2025
|
PRIMARY | |||
|
SUB179894
Created by
admin on Mon Mar 31 18:45:54 GMT 2025 , Edited by admin on Mon Mar 31 18:45:54 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |